Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm

Key Points

• Dermatologic toxicities related to amivantamab can significantly impact patient quality of life, showing the need for timely management.
• Specifically, experts recommend an algorithm to effectively prevent and manage these toxicities, improving patient outcomes.
• This consensus was formed through a professional gathering of dermatological and oncology specialists, emphasizing the importance of collaboration.
• Implementation could enhance patient care strategies in clinical settings across Europe, addressing a common adverse event.

Abstract

No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.